

- VI. Claim 28, drawn to methods of screening based on an antibody reagent usage, classified in class 435, subclass 7.1;
- VII. Claims 29, 49 and 50, drawn to methods of detection based on polypeptide reagent usage, classified in class 435, subclass 7.1;
- VIII. Claims 32-43, drawn to immunogenic polypeptides and methods of administration of them, classified in classes 424 and 514, subclasses 184.1 and 2, respectively; and
- IX. Claims 44-47, drawn to immunogenic DNAs, classified in class 514, subclass 44.

The Examiner contends that the inventions are distinct, each from the other. In response, Applicants hereby elect, with traverse, to prosecute the claims of Group I (Claims 1-16, 30, 51 and 52), drawn to polynucleotides, vectors, and genetically engineered host cells containing said polynucleotides.

The Examiner has also required an election of up to 10 nucleic acid sequences for Group I, Claims 1-16, 30, 51 and 52. In response, Applicants hereby elect, with traverse, the following 10 nucleic acid sequences: ORF 1083, ORF 1089, ORF 1091, ORF 1095, ORF 1096, ORF 1105, ORF 1117, ORF 1140, ORF 1159, and ORF 1167.

No fee is believed to be due for the filing of this response. However, in the event a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.


Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

Date August 16, 2000

  
\_\_\_\_\_  
Laura A. Coruzzi 30,742  
(Reg. No.)

By:

  
\_\_\_\_\_  
Nikolaos C. George 39,201  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, NY 10036  
(212) 790-9090

Enclosure